Merck & Co. Inc.’s (MRK) Prevymis for the expanded use in prophylaxis of cytomegalovirus disease in adult kidney transplant recipients at high risk awaits the FDA decision on June 5, 2023.In clinical setting, Prevymis demonstrated non-inferior efficacy and a more favorable safety profile compared to Valganciclovir, the current standard of care for cytomegalovirus (CMV) prophylaxis in kidney transplant recipients.Prevymis was approved in the U.S. in 2017 for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).The drug generated sales of $428 million in full-year 2022, and $129 million in the first quarter of 2023.MRK closed Friday’s (May 26, 2023) trading at $111.07, down 1.10%.